Gordon L Amidon

List of Publications by Year in Descending Order

153 papers	14,023 citations	48 h-index	117 g-index
157 ext. papers	15,030 ext. citations	4.6 avg, IF	6.16 L-index

#	Paper	IF	Citations
153	Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling.. *AAPS Journal*, **2022**, 24, 17	3.7	3
152	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. *Pharmaceutics*, **2021**, 13,	6.4	2
151	Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. *Molecular Pharmaceutics*, **2021**, 18, 3326-3341	5.6	1
150	Biphasic Dissolution as an Exploratory Method During Early Drug Product Development. *Pharmaceutics*, **2020**, 12,	6.4	4
149	Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). *Pharmaceutics*, **2020**, 12,	6.4	3
148	Chemoproteomic Identification of Serine Hydrolase RBBP9 as a Valacyclovir-Activating Enzyme. *Molecular Pharmaceutics*, **2020**, 17, 1706-1714	5.6	8
147	A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children. *European Journal of Pharmaceutical Sciences*, **2020**, 152, 105437	5.1	4
146	A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP. *Pharmaceutics*, **2020**, 12,	6.4	25
145	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. *PLoS ONE*, **2020**, 15, e0241441	3.7	3
144	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. *European Journal of Pharmaceutical Sciences*, **2020**, 155, 105517	5.1	13
143	Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel. *Molecular Pharmaceutics*, **2020**, 17, 3870-3884	5.6	7
142	The in vivo predictive dissolution for immediate release dosage of donepezil and danazol, BCS class IIc drugs, with the GIS and the USP II with biphasic dissolution apparatus. *Journal of Drug Delivery Science and Technology*, **2020**, 56, 100920	4.5	4
141	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants **2020**, 15, e0241441		
140	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants **2020**, 15, e0241441		
139	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants **2020**, 15, e0241441		
138	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants **2020**, 15, e0241441		
137	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants **2020**, 15, e0241441		

136	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants **2020**, 15, e0241441		
135	Propagation Characteristics of Fasting Duodeno-Jejunal Contractions in Healthy Controls Measured by Clustered Closely-spaced Manometric Sensors. *Journal of Neurogastroenterology and Motility*, **2019**, 25, 100-112	4.4	5
134	Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: The hidden role of bicarbonate buffer. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 142, 8-19	5.7	18
133	Mass Transport Analysis of Bicarbonate Buffer: Effect of the CO-HCO Hydration-Dehydration Kinetics in the Fluid Boundary Layer and the Apparent Effective p K Controlling Dissolution of Acids and Bases. *Molecular Pharmaceutics*, **2019**, 16, 2626-2635	5.6	25
132	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. *Pharmaceutics*, **2019**, 11,	6.4	9
131	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. *AAPS Journal*, **2019**, 22, 3	3.7	3
130	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. *AAPS Journal*, **2018**, 20, 57	3.7	16
129	Improved Protease-Targeting and Biopharmaceutical Properties of Novel Prodrugs of Ganciclovir. *Molecular Pharmaceutics*, **2018**, 15, 410-419	5.6	2
128	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach. *European Journal of Pharmaceutical Sciences*, **2018**, 115, 258-269	5.1	29
127	Pulse Packet Stochastic Model for Gastric Emptying in the Fasted State: A Physiological Approach. *Molecular Pharmaceutics*, **2018**, 15, 2107-2115	5.6	8
126	The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene. *Journal of Pharmaceutical Sciences*, **2018**, 107, 307-316	3.9	28
125	Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice. *Biochemical Pharmacology*, **2018** , 156, 147-156	6	3
124	Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. *British Journal of Clinical Pharmacology*, **2018**, 84, 2231-2241	3.8	12
123	Mechanistic Basis of Cocrystal Dissolution Advantage. *Journal of Pharmaceutical Sciences*, **2018**, 107, 380-389	3.9	10
122	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed State. *Molecular Pharmaceutics*, **2018**, 15, 5468-5478	5.6	10
121	Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate-CO Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance. *Molecular Pharmaceutics*, **2018**, 15, 5291-5301	5.6	19
120	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions. *Molecular Pharmaceutics*, **2018**, 15, 5454-5467	5.6	18
119	In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. *AAPS Journal*, **2018**, 20, 100	3.7	7

118	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. *European Journal of Pharmaceutics and Biopharmaceutics*, **2018**, 129, 162-174	5.7	18
117	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded 21st Century BA/BE project. *International Journal of Pharmaceutics*, **2018**, 548, 120-127	6.5	27
116	Utilization of Gastrointestinal Simulator, an in Vivo Predictive Dissolution Methodology, Coupled with Computational Approach To Forecast Oral Absorption of Dipyridamole. *Molecular Pharmaceutics*, **2017**, 14, 1181-1189	5.6	20
115	The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS). *European Journal of Pharmaceutical Sciences*, **2017**, 102, 126-139	5.1	33
114	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. *International Journal of Pharmaceutics*, **2017**, 519, 79-97	6.5	68
113	Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. *Molecular Pharmaceutics*, **2017**, 14, 345-358	5.6	30
112	In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. *Molecular Pharmaceutics*, **2017**, 14, 4295-4304	5.6	36
111	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs. *Molecular Pharmaceutics*, **2017**, 14, 4281-4294	5.6	66
110	Oral product input to the GI tract: GIS an oral product performance technology. *Frontiers of Chemical Science and Engineering*, **2017**, 11, 516-520	4.5	1
109	Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. *AAPS Journal*, **2017**, 19, 1682-1690	3.7	14
108	In Vitro Characterization of the Biomimetic Properties of Poly(dimethylsiloxane) To Simulate Oral Drug Absorption. *Molecular Pharmaceutics*, **2017**, 14, 4661-4674	5.6	6
107	Magnetic Resonance Imaging Quantification of Fasted State Colonic Liquid Pockets in Healthy Humans. *Molecular Pharmaceutics*, **2017**, 14, 2629-2638	5.6	35
106	Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine. *Molecules*, **2017**, 22,	4.8	8
105	Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization. *Molecular Pharmaceutics*, **2016**, 13, 1030-46	5.6	30
104	Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue. *Journal of Pharmaceutical Sciences*, **2016**, 105, 925-934	3.9	16
103	Gastrointestinal Motility Variation and Implications for Plasma Level Variation: Oral Drug Products. *Molecular Pharmaceutics*, **2016**, 13, 557-67	5.6	27
102	The Evaluation of In Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media. *Journal of Pharmaceutical Sciences*, **2016**, 105, 2804-2814	3.9	38
101	Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes. *Molecular Pharmaceutics*, **2015**, 12, 3399-407	5.6	17

100	In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents. *Molecular Pharmaceutics*, **2015**, 12, 2418-28	5.6	39
99	In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. *European Journal of Pharmaceutical Sciences*, **2015**, 76, 203-12	5.1	48
98	In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate and Phosphate Buffer on the Dissolution of Weak Acids and Weak Bases. *Journal of Pharmaceutical Sciences*, **2015**, 104, 2894-904	3.9	50
97	The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 152-63	5.1	185
96	G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS. *AAPS Journal*, **2014**, 16, 894-8	3.7	81
95	Synthesis and characterization of valyloxy methoxy luciferin for the detection of valacyclovirase and peptide transporter. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4781-4783	2.9	15
94	Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. *Molecular Pharmaceutics*, **2014**, 11, 3039-47	5.6	271
93	Bio-predictive tablet disintegration: effect of water diffusivity, fluid flow, food composition and test conditions. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 273-9	5.1	28
92	In vivo predictive dissolution: transport analysis of the CO2 , bicarbonate in vivo buffer system. *Journal of Pharmaceutical Sciences*, **2014**, 103, 3473-3490	3.9	61
91	Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution. *Journal of Pharmaceutical Sciences*, **2014**, 103, 3416-3422	3.9	55
90	Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. *Molecular Pharmaceutics*, **2013**, 10, 958-66	5.6	50
89	Cytomegalovirus protease targeted prodrug development. *Molecular Pharmaceutics*, **2013**, 10, 1417-24	5.6	13
88	Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus. *Biopharmaceutics and Drug Disposition*, **2012**, 33, 378-402	1.7	59
87	In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. *Biopharmaceutics and Drug Disposition*, **2012**, 33, 366-77	1.7	64
86	Oral Bioavailability of Peptide and Peptidomimetic Drugs **2011**, 277-292		1
85	Provisional BCS Classification of the Leading Oral Drugs on the Global Market **2010**, 353-366		
84	Physiological parameters for oral delivery and in vitro testing. *Molecular Pharmaceutics*, **2010**, 7, 1388-405	5.6	287
83	High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. *Molecular Pharmaceutics*, **2010**, 7, 1827-34	5.6	84

82	Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. *Molecular Pharmaceutics*, **2009**, 6, 29-39	5.6	69
81	Gastrointestinal Dissolution and Absorption of Class II Drugs. *Methods and Principles in Medicinal Chemistry*, **2008**, 33-51	0.4	14
80	Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. *AAPS Journal*, **2008**, 10, 373-9	3.7	48
79	Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. *European Journal of Pharmaceutical Sciences*, **2006**, 29, 306-14	5.1	89
78	Nucleoside ester prodrug substrate specificity of liver carboxylesterase. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 572-80	4.7	36
77	The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. *Molecular Pharmaceutics*, **2006**, 3, 686-94	5.6	119
76	A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. *Molecular Pharmaceutics*, **2006**, 3, 631-43	5.6	416
75	Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs. *Molecular Pharmaceutics*, **2005**, 2, 37-46	5.6	36
74	Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. *Molecular Pharmaceutics*, **2004**, 1, 85-96	5.6	597
73	Lessons learned from marketed and investigational prodrugs. *Journal of Medicinal Chemistry*, **2004**, 47, 2393-404	8.3	304
72	Gastrointestinal Dissolution and Absorption of Drugs. *Methods and Principles in Medicinal Chemistry*, **2003**, 189-214	0.4	3
71	Transporters in the GI Tract. *Methods and Principles in Medicinal Chemistry*, **2003**, 243-287	0.4	3
70	Biopharmaceutics classification system: the scientific basis for biowaiver extensions. *Pharmaceutical Research*, **2002**, 19, 921-5	4.5	393
69	Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein. *AAPS PharmSci*, **2001**, 3, E2		16
68	Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. *Pharmaceutical Research*, **2000**, 17, 439-44	4.5	68
67	Targeted prodrug design to optimize drug delivery. *AAPS PharmSci*, **2000**, 2, E6		168
66	Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. *AAPS PharmSci*, **2000**, 2, E16		38
65	Dissolution studies as surrogate for bioequivalence. *European Journal of Drug Metabolism and Pharmacokinetics*, **2000**, 25, 65-65	2.7	

64	Designing Prodrugs for the hPEPT1 Transporter. *ACS Symposium Series*, **2000**, 46-53	0.4	
63	A compartmental absorption and transit model for estimating oral drug absorption. *International Journal of Pharmaceutics*, **1999**, 186, 119-25	6.5	357
62	The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. *Pharmaceutical Research*, **1999**, 16, 272-80	4.5	36
61	"5RAmino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter,". *Pharmaceutical Research*, **1999**, 16, 175	4.5	6
60	A pH- and ionic strength-responsive polypeptide hydrogel: synthesis, characterization, and preliminary protein release studies. *Journal of Biomedical Materials Research Part B*, **1999**, 47, 595-602		98
59	First-pass metabolism of peptide drugs in rat perfused liver. *Journal of Pharmacy and Pharmacology* , **1998**, 50, 1013-8	4.8	15
58	5RAmino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. *Pharmaceutical Research*, **1998**, 15, 1154-9	4.5	249
57	Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. *Pharmaceutical Research*, **1998**, 15, 1382-6	4.5	78
56	Drug marker absorption in relation to pellet size, gastric motility and viscous meals in humans. *Pharmaceutical Research*, **1998**, 15, 233-8	4.5	19
55	Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. *Pharmaceutical Research*, **1998**, 15, 11-22	4.5	748
54	Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. *Pharmaceutical Research*, **1998**, 15, 1348-55	4.5	61
53	Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. *Pharmaceutical Research*, **1998**, 15, 1376-81	4.5	16
52	Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. *Biopharmaceutics and Drug Disposition*, **1998**, 19, 169-74	1.7	17
51	Factors that influence stability of recombinant adenoviral preparations for human gene therapy. *Pharmaceutical Development and Technology*, **1998**, 3, 373-83	3.4	62
50	Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery. *Pharmaceutical Development and Technology*, **1998**, 3, 365-72	3.4	31
49	The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. *Pharmaceutical Research*, **1997**, 14, 1568-73	4.5	655
48	Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. *Pharmaceutical Research*, **1997**, 14, 1127-32	4.5	45
47	The absence of accessible vitronectin receptors in differentiated tissue hinders adenoviral-mediated gene transfer to the intestinal epithelium in vitro. *Pharmaceutical Research*, **1997**, 14, 1216-22	4.5	15

46	Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. *Clinical Pharmacology and Therapeutics*, **1997**, 61, 531-43	6.1	57
45	Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. *Advanced Drug Delivery Reviews*, **1996**, 19, 359-76	18.5	261
44	Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharmaceutical Research*, **1996**, 13, 1838-45	4.5	703
43	Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. *Pharmaceutical Research*, **1996**, 13, 1631-4	4.5	38
42	Effect of micronization on the extent of drug absorption from suspensions in humans. *Archives of Pharmacal Research*, **1995**, 18, 427-433	6.1	24
41	Functional expressions of endogenous dipeptide transporter and exogenous proton/peptide cotransporter inXenopus oocytes. *Archives of Pharmacal Research*, **1995**, 18, 12-17	6.1	1
40	A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharmaceutical Research*, **1995**, 12, 413-20	4.5	3518
39	Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. *Pharmaceutical Research*, **1995**, 12, 780-6	4.5	28
38	The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. *Journal of Clinical Pharmacology*, **1995**, 35, 374-8	2.9	12
37	Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. *Biopharmaceutics and Drug Disposition*, **1994**, 15, 719-46	1.7	38
36	The role of rheological properties in mucociliary transport by frog palate ciliated model. *Pharmaceutical Research*, **1994**, 11, 1785-91	4.5	6
35	Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. *Pharmaceutical Research*, **1994**, 11, 528-35	4.5	43
34	Description and simulation of a multiple mixing tank model to predict the effect of bile sequestrants on bile salt excretion. *Journal of Pharmaceutical Sciences*, **1993**, 82, 311-8	3.9	19
33	Peptide carrier-mediated transport in intestinal brush border membrane vesicles of rats and rabbits: cephradine uptake and inhibition. *Pharmaceutical Research*, **1993**, 10, 400-4	4.5	22
32	Viscoelasticity of anionic polymers and their mucociliary transport on the frog palate. *Pharmaceutical Research*, **1993**, 10, 411-7	4.5	17
31	Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. *Pharmaceutical Research*, **1993**, 10, 264-70	4.5	191
30	An investigation into the mechanical and transport properties of aqueous latex films: a new hypothesis for the film-forming mechanism of aqueous dispersion system. *Pharmaceutical Research*, **1993**, 10, 405-10	4.5	25
29	Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: theoretical development and applications. *Pharmaceutical Research*, **1993**, 10, 271-5	4.5	23

28	Viscoelastic properties of polyacrylic acid gels in mixed solvents. *Pharmaceutical Research*, **1992**, 9, 1659-63	4.5	31
27	Equilibrium and kinetic factors influencing bile sequestrant efficacy. *Pharmaceutical Research*, **1992**, 9, 670-6	4.5	15
26	Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. *Pharmaceutical Research*, **1992**, 9, 969-78	4.5	119
25	Viscometric study of polyacrylic acid systems as mucoadhesive sustained-release gels. *Pharmaceutical Research*, **1991**, 8, 1408-12	4.5	22
24	Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. *Pharmaceutical Research*, **1991**, 8, 298-305	4.5	25
23	Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. *Pharmaceutical Research*, **1991**, 8, 698-705	4.5	13
22	Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. *Pharmaceutical Research*, **1991**, 8, 93-6	4.5	43
21	Structural requirements for the intestinal mucosal-cell peptide transporter: the need for N-terminal alpha-amino group. *Pharmaceutical Research*, **1991**, 8, 593-9	4.5	41
20	Mixture experimental design in the development of a mucoadhesive gel formulation. *Pharmaceutical Research*, **1991**, 8, 1401-7	4.5	29
19	Stereoselective systemic disposition of ibuprofen enantiomers in the dog. *Pharmaceutical Research*, **1991**, 8, 1186-90	4.5	20
18	Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. *Pharmaceutical Research*, **1991**, 8, 1500-4	4.5	32
17	Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. *Pharmaceutical Research*, **1991**, 8, 979-88	4.5	128
16	Effects of gravity on gastric emptying, intestinal transit, and drug absorption. *Journal of Clinical Pharmacology*, **1991**, 31, 968-73	2.9	60
15	The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. *Gastroenterology*, **1990**, 99, 1275-82	13.3	144
14	The effect of physical aging on the dissolution rate of anionic polyelectrolytes. *Pharmaceutical Research*, **1990**, 7, 648-53	4.5	19
13	Mechanism of absorption of the dipeptide alpha-methyldopa-phe in intestinal brush-border membrane vesicles. *Pharmaceutical Research*, **1990**, 7, 308-9	4.5	36
12	The molecular weight dependence of nasal absorption: the effect of absorption enhancers. *Pharmaceutical Research*, **1990**, 7, 808-15	4.5	56
11	Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport. *Pharmaceutical Research*, **1990**, 7, 1099-106	4.5	44

10	Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. *Pharmaceutical Research*, **1990**, 7, 863-8	4.5	132
9	In Vitro and in Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms. *Pharmaceutical Research*, **1990**, 07, 975-982	4.5	58
8	Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa. *Pharmaceutical Research*, **1989**, 6, 66-70	4.5	75
7	The estimation of solubility in binary solvents: application of the reduced 3-suffix solubility equation to ethanol-water mixtures. *Pharmaceutical Research*, **1988**, 5, 193-5	4.5	29
6	Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. *Pharmaceutical Research*, **1988**, 5, 651-4	4.5	239
5	Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. *Pharmaceutical Research*, **1988**, 5, 645-50	4.5	75
4	pH-dependent swelling and solute diffusion characteristics of poly(hydroxyethyl methacrylate-co-methacrylic acid) hydrogels. *Pharmaceutical Research*, **1988**, 5, 592-7	4.5	114
3	The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. *Journal of Pharmacokinetics and Pharmacodynamics*, **1987**, 15, 529-44		163
2	Pharmacokinetics of alcohol following single low doses to fasted and nonfasted subjects. *Journal of Clinical Pharmacology*, **1977**, 17, 199-206	2.9	45
1	Provisional BCS Classification of the Leading Oral Drugs on the Global Market1-14		